Advertisement

Topics

Guidance Concerns Grow As Mylan's Drug Approvals Are Delayed

10:23 EDT 3 Aug 2017 | Topix

Shares have drifted downward on fears that the company could lower 2017 guidance when they report 2Q results on August 9th. Specifically, investors are concerned about the guidance for $850 million in revenue from new drugs, with Copaxone and Advair generics receiving FDA setbacks in recent months.

Original Article: Guidance Concerns Grow As Mylan's Drug Approvals Are Delayed

NEXT ARTICLE

More From BioPortfolio on "Guidance Concerns Grow As Mylan's Drug Approvals Are Delayed"

Quick Search
Advertisement